INTRODUCTION
In eukaryotic cells, the CoA esters of long-chain fatty acids (LCFA) undergo f-oxidation within the mitochondrial matrix but they do not readily cross the inner mitochondrial membrane. A specific mechanism has evolved for transporting LCFAs into the mitochondria which requires the transfer of the fatty acid moiety from the acyl-CoA ester to L-carmitine by carnitine palmitoyltransferase I (CPT-I). The acyl-carnitine conjugate is translocated across the inner mitochondrial membrane and then converted back to the acyl-CoA ester by carnitine palmitoyltransferase II (CPT-II) [1] [2] [3] . This transport process may be a rate-limiting step in fatty acid metabolism [3] with feedback regulation exerted on CPT-I by malonyl-CoA, an intermediate in fatty acid biosynthesis [3, 4] . In addition, tissue-specific regulation of fatty acid oxidation in heart and liver indicates that there may be tissue-specific isoforms of CPT-I. This hypothesis is consistent with biochemical analyses of CPT-I from these tissues [5] [6] [7] .
Interest in CPT has increased due to findings linking gluconeogenesis in non-insulin-dependent diabetes (NIDDM) to fatty acid oxidation [8] . First, CPT activity appears to be regulated by insulin [9] [10] [11] . In streptozotocin-treated diabetic rats, hepatic CPT-I activity was increased whereas the sensitivity of the enzyme to malonyl-CoA inhibition was decreased [9, 10] . Administration of insulin reversed both the stimulatory effect of diabetes on CPT-I activity and the induced insensitivity of the enzyme to malonyl-CoA regulation [9, 10] . Secondly, recessively inherited deficiencies in CPT activity (which are sometimes fatal) have been associated with non-ketotic hypoglycaemia [12] [13] [14] [15] . Finally, hyperglycaemic diabetic animals and humans that have been treated with agents known to inhibit CPT-I activity, i.e. methyl 2-tetradecylglycidate, Clomoxir or Etomoxir, showed decreased blood glucose levels [16] [17] [18] [19] .
of active rCPT-II were chromatographically purified from largescale cultures of insect cells infected with the recombinant baculovirus. The rCPT-II was found to be: (1) While the above CPT inhibitors are effective hypoglycaemic agents, their use in the treatment of NIDDM is limited by the finding of undesirable side-effects in animals [8, 18] . Deleterious responses to Etomoxir and Clomoxir have been attributed to irreversible inhibition of CPT-I actvity [18, [20] [21] [22] . Reversible inhibition of CPT-I activity, on the other hand, may be a reasonable compromise in the development ofsafe and efficacious drugs for the treatment of NIDDM. As a first step in defining the biochemical and biophysical properties of CPT for drug development, recombinant CPT-II (rCPT-II) was over-expressed in insect cells, purified and characterized. CPT-II was chosen as a model for CPT-I because of the inherent difficulties involved in purifying and retaining CPT-I activity. Although biochemically similar to CPT-II, CPT-I appears to be an integral membranebound protein which loses activity upon solubilization [6, 23] . On the other hand, CPT-II is loosely associated with the mitochondrial membrane and retains carnitine transferase activity when isolated in soluble form [6, 23] .
Methods

Microbial cultures and plasmid isolation
The pBKS-CPT 11.4 clone was provided by Dr. J. Denis McGarry (Departments of Internal Medicine and Biochemistry, University of Texas Southwestern Medical Center) [24] . The pBKS(-) plasmid (Stratagene) containing CPT-II.4 cDNA was propagated in Escherichia coliXL-1 BLUE (Stratagene), isolated and purified using Magic Minipreps plasmid purification kit (Promega). The pVL-1393 baculovirus transfer vector (Invitrogen) was propagated in E. coli XL-1 BLUE, isolated and purified as described above.
Abbreviations used: LCFA, long-chain fatty acid; NIDDM, non-insulin-dependent diabetes; CPT-I, carnitine palmitoyltransferase I; CPT-Il, carnitine palmitoyltransferase 11; rCPT-Il, recombinant carnitine palmitoyltransferase 11; AcMNPV, Autographa californica nuclear polyhedrosis virus; ATT CAT TAC TAA GTT TTG ATG-3' respectively. The 2.0 kb PCR product was cloned into pBKS(-), sequenced and then subcloned into the baculovirus expression vector pVL-1393 using standard cloning procedures [25] .
DNA sequencing of the CPT-ll PCR products DNA sequencing following the Sanger dideoxynucleotide chaintermination method [26] Construction of recombinant baculovirus, screening and plaque purification Co-transfection of pVL-1393-CPT-II with AcMNPV DNA (Invitrogen or PharMingen) into Spodopterafrugiperda cells (SF-9) was performed as previously described [27] . Transfected cultures were maintained for at least 84 h at 27°C and recombinant AcMNPVs were identified and purified by plaque assay [27, 28] . Screening for rCPT-II expression was done using a rabbit anti-CPT-II polyclonal serum (obtained from Dr. J. Denis McGarry) diluted 1: 500 as described elsewhere [27, 28] . A recombinant baculovirus clone, CPTIIBG.2B, was identified, plaquepurified twice and used throughout these experiments.
Isolation of total cellular DNA from AcMNPV-infected SF-9 cells and Southern-blot analysis Confluent SF-9 cells in three 25 cm2 flasks were either mockinfected or infected with wild-type or recombinant CPTIIBG.2B AcMNPVs at a multiplicity of infection (MOI) of 10. The cells were incubated for 72 h at 27 'C. Total DNA from the infected SF-9 cells was isolated [28] , digested with EcoRI/SmaI and separated on a 1 % agarose gel. The DNA was Southern transferred [29] to a nylon membrane and probed with biotinylated CPT-II cDNA (Images kit, USB). Size marker, 1 kb ladder, was purchased from Gibco/BRL. The blot was exposed to Hyperfilm (Amersham) for 15 min.
Expression of rCPT-11
For the initial small-scale evaluation of rCPT-II expression, infected insect cells were incubated in 25 cm2 flasks for 72 h at 27 'C, after which the cells were removed and pelleted at 500 g for 5 min at 4 'C. After decanting the supernatants, the cell pellets were immediately frozen in a dry-ice/ethanol bath and stored at -70 'C until assayed. For large-scale production and purification of rCPT-II, suspension cultures (500 ml, 3 x 106 lated with recombinant baculovirus CPTIIBG.2B at an MOI of 10. After 72 h the cells were harvested by centrifugation (750 g, 4°C), washed once with PBS and stored at -70 'C. For both small-and large-scale samples, SF-9 cells were lysed using a combination of freeze/thaw cycles and hypotonic lysis in 5 mM potassium phosphate buffer (pH 7.5; 16-35 ml/1010 cells) containing the protease inhibitors phenylmethanesulphonyl fluoride (PMSF) (1 mM), leupeptin (10,uM) and pepstatin (1 1zM). nOctyl glucoside (1 % w/v) was added to each sample which was then mixed for 30 min at 4 'C. The large-scale sample was treated further by centrifugation at 140000 g at 4 'C for 60 min. The clear portion of the supernatant was removed and stored at 4 'C. The pellet and denser phase were re-extracted with lysis buffer (44-70 ml/1010 cells) containing n-octyl glucoside (1 % w/v) and re-centrifuged. The clear portion of the supernatant was pooled with the first.
Protein purification A modified method of Miyazawa et al. [30] was used to isolate rCPT-II. Crude rCPT-II was batch-adsorbed to DEAE-cellulose equilibrated in Fractions containing rCPT-II activity were pooled, concentrated and dialysed against 5 mM potassium phosphate/0.5 % (v/v) Tween 20, pH 7.5. As a final step, the rCPT-II sample was applied to DEAE-agarose equilibrated with 5 mM potassium phosphate/0.5 % (v/v) Tween 20, pH 7.5. The column was washed with 5 mM potassium phosphate/0.5 % (v/v) Tween 20, pH 7.5, and rCPT-II was eluted with a linear salt gradient up to 20 mM potassium phosphate/ 0.5 % (v/v) Tween 20, pH 7.5. In some instances, fractions containing rCPT-II were pooled and subjected to another round of DEAE-agarose ion-exchange chromatography as described above. Purified rCPT-II was stored ( ; 1 mg/ml) at -70 'C.
Carnitine transferase activity assays rCPT-II activity was determined by: (1) the production of palmitoyl-[14C]carnitine from [14C]carnitine in the presence of 1 % (w/v) BSA [4] ; or (2) the reduction of 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) by CoASH in the absence of BSA [31] . Km values for carnitine and palmitoyl-CoA were determined as described above [31] at 37 'C in the presence of 0.2 mM DTNB over a range of substrate concentrations (50-750 uM Lcarnitine, 25-400,M palmitoyl-CoA) in 150 mM Tris-HCl buffer (pH 7.2). Km values were estimated by analysing the data from three experiments performed in triplicate using the GraFit program (version 2.0) [32] . All protein concentrations were determined using the DC protein assay system (Bio Rad) with BSA as the standard.
Protein charactedzation SDS/PAGE, isoelectric focusing, silver staining and Western transfer were performed using a PhastSystem apparatus cells/ml in logarithmic growth, 27 'C) of SF-9 cefls were inocu-(Pharmacia). SDS/PAGE and Western/immunodetection were also performed as described elsewhere [28] . An Ultroscan XL analyzer (Pharmacia) was used for densitometry. Glycosylation was investigated by enzyme-linked immunoasssay ofdigoxigeninlabelled glycoconjugates (Glycan Detection Kit, Boehringer Mannheim Biochemica), using transferrin and cl-acid glycoprotein as positive controls. Protein sequence was determined on an Applied Biosystem 477A Protein Sequencer after removal of Tween 20 using pre-packed 'Extracti-Gel D' columns (Pierce).
The CPT-II.4 cDNA clone [24] was altered by removing both 5 (Figure 2) .
CPT activity of rCPT-II was assayed initially using radio- The total cellular protein from mock-, wild-type-and CPTIIBG.2B-infected-SF-9 cell lysates was separated by SDS/PAGE, transferred to nitrocellulose and probed with anti-CPT-11 polyclonal antibodies. Samples from each of the lysates ( than with palmitoyl-CoA ( Figure 3 ). The observed activity profile did not correlate directly with substrate solubility, since acylCoAs of carbon chain length 8-C810 were preferred over those of C4-C6. This type of activity profile for the forward reaction of CPT-II with acyl-CoAs of different chain-length is similar to that reported for mitochondrial rat liver, chicken embryo liver and bovine heart CPT-II [33] [34] [35] . Moreover, the C8 and C10 transferase activities were partially inhibited by the addition of 1 % noctyl glucoside (results not shown). This type of inhibition has previously been reported for native CPT-II [36] . In contrast to C8
and C10 substrates, the C16 transferase activity was identical in both the soluble and insoluble cell fractions and was not sensitive to octyl glucoside inhibition. Finally, no inhibition of enzyme activity was observed for any of the substrates in both the soluble and insoluble rCPT-II fractions upon the addition of 50,aM malonyl-CoA (inhibitor of CPT-I activity). The production of rCPT-II was scaled-up for purification of the enzyme, based on the parameters described above. Table 1 summarizes representative specific activities, total units, percentage yield and fold-purification after the various purification steps. Typically, about 65-80 % of the total CPT activity from the cell extract was adsorbed to the DEAE-cellulose matrix in the first step of purification. Different batches of purification yielded different amounts of soluble rCPT-II. The highest recovery of enzyme was 1.8 mg of soluble rCPT-II per litre of cell culture from batch rCPT-IIF. The rCPT-IIF batch of enzyme yielded a total of about 32 mg of purified soluble CPT-II and was used throughout this study. SDS/PAGE of purified rCPT-II showed a single protein band which migrated with an apparent molecular mass similar to that of native rat liver CPT-II ( -70 kDa) (Figure 4 ; see Figure 2 for Western blot of crude enzyme preparation). Densitometric analysis of the silver-stained gel indicated that the rCPT-II was > 95 % pure. Furthermore, this material was immunoreactive with the anti-CPT-II polyclonal serum (Figure 4) . To confirm the identity of rCPT-II, the purified enzyme was subjected to 15 cycles of N-terminal amino acid sequence analysis. The sequence information provided evidence authenticating rCPT-II and, at the same time, revealed the existence of two rCPT-II isoforms that were present in similar amounts. The N-terminal amino acids of the two isoforms were determined to be Leu-25 and Ser-26 of the deduced rat liver CPT-II amino acid sequence [24] .
Isoelectric focusing in polyacrylamide gels revealed similar isoelectric points (pl) for both native and recombinant CPT-II, band (pl 6.2-6.4) was observed in the rCPT-II sample (results not shown). It is believed that the second isoelectric point can be explained by the different amino acids at the N-termini of the two proteins and/or by deamidation, because no evidence for glycosylation was seen in different preparations (n = 3) of rCPT-II or in samples of the native enzyme (results not shown).
The kinetic parameters of purified soluble rCPT-II were determined using the assay method of Bieber and Fiol [31] (see Methods section). Under the conditions used, Km values were calculated to be 950 + 27 ,uM for carnitine and 34 + 5.6 ,uM for palmitoyl-CoA. rCPT-II activity was also assayed under different pH conditions and after various storage and handling procedures. No loss in activity was observed after six freeze/thaw cycles (-70°C/room temperature) or after storage at room temperature (6.5 h). Moreover, soluble rCPT-II maintained activity in different buffers over the pH range 7-10. Storage in these buffers for 24 h at 4 'C did not appear to affect enzyme activity.
DISCUSSION
Previous attempts to over-express active CPT-II in E. coli or in yeast have resulted in either low levels of expression (in yeast) or mainly insoluble recombinant protein (E. coli). In contrast, milligram quantities ofsoluble rat liver rCPT-II could be obtained using the baculovirus expression system. Interestingly, two isoforms of soluble rCPT-II, present in similar amounts, were produced in the insect cell system. One isomer had a pl which was similar to that of native rat liver CPT-II (pH 6.4-6.5) and the other had a pl which was slightly lower (pH 6.2-6.4). The two isoforms appeared to differ by only a single amino acid, Native rat liver CPT-II is believed to contain an N-terminal mitochondrial leader sequence that is cleaved during processing and translocation of the enzyme into the mitochondrial membrane [24] . The insect cells were capable of recognizing and processing the CPT-II rat liver mitochondrial leader sequence, since the first 24-25 amino acids were not found in the Nterminal sequence of the mature rCPT-II isoenzymes. Furthermore the microsequencing data showed no evidence of contamination by other non-related proteins. The difference in the N-termini of the two rCPT-II isoforms was most likely due to differential cleavage by the insect cells during post-translational modification or proteolytic degradation.
Together, the rCPT-II isoforms represented > 95 % of the total protein in the purified enzyme preparation. The purified material was of the same apparent size as rat liver CPT-II, showed similar activity over a wide pH range (pH 7-10) and appeared to be stable at room temperature in phosphate buffer containing 0.5 % Tween 20. In buffers of pH below the pl of rCPT-II (6.5), the rate of catalysis declined sharply. Histidine is the only titratable amino acid with an R group that has a pKa in this pH range (pK. of 6.0). Moreover, a histidine residue (CPT-II, His-372) is conserved among all members of the carnitine acyltransferase family of enzymes and a histidine residue is believed to be involved in carnitine acetyltransferase catalysis [37] . Based on this information, it is likely that a histidine residue is also involved in reactions catalysed by CPT-II.
Slightly different Km values for mitochondrial CPT-II, isolated from various species and tissues, have previously been reported [33, 38, 39] . Although not specified, it is assumed that these kinetic analyses were performed with CPT-II and not CPT-I. Some of the kinetic variations observed may be attributed to speciesspecific isoforms of CPT-II. However, rat and human liver CPT-II are approximately 80 % homologous [40] , with near identity in certain regions of the protein that may be involved in substrate binding. Since tissue-specific isoforms of CPT-II have not been reported, and given the high degree of homology among species, variations in the kinetic characterization of this enzyme are more likely to be due to differences in experimental assay conditions and methods of purification. In general, however, the Km values for carnitine and palmitoyl-CoA are around 1-1.5 mM and 10-60 uM respectively. The kinetic parameters determined for rCPT-II were similar to those of mitochondrial CPT-II isolated from chick embryo liver [33] , and in general, fell within the range determined for the various samples of CPT-II as described above. On the other hand, comparison of the kinetic values for rCPT-II with those determined for rat liver mitochondrial CPT-I indicated that the Km for palmitoyl-CoA (CPT-I, Km 30-60 ,uM) is similar for both enzymes, while CPT-I has a much lower Km for carnitine (Km 32 + 1.4 ,uM) [41] . Also, when assayed under similar conditions (100 ,#M palmitoyl-CoA/200 ,uM carnitine/l % BSA) the specific activity of purified rCPT-II (460 nmol/min per mg of protein) was 50-70-fold greater than that of CPT-I from intact rat liver mitochondria.
Finally, the activity of rCPT-II associated with the soluble and insoluble fractions of insect cell lysates was assayed using acylCoA substrates of different chain length in the absence of detergent. The ratio of enzyme activity in the soluble to insoluble fractions varied depending on the specific acyl-CoA substrate tested, approaching unity only with butyryl-and palmitoyl-CoA substrates. These differential activities may reflect differences in the affinity of the rCPT-II for acyl-CoA substrates of varying chain-length, depending on the presence or absence of a membrane environment, and/or differential but direct effects of the acyl-CoA substrates on the physical environment of the enzyme in the two fractions. A similar sensitivity to environment has been observed with CPT-I, where the enzyme is sensitive to malonyl-CoA inhibition only when associated with the membrane [4] .
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